List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/811672/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Dosimetric comparison of intensity modulated radiotherapy and intensity modulated proton therapy in the treatment of recurrent nasopharyngeal carcinoma. Medical Dosimetry, 2022, 47, 14-19.	0.9	5
2	Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients. Clinical and Translational Radiation Oncology, 2022, 32, 59-68.	1.7	18
3	In Reply to Abbasi et al International Journal of Radiation Oncology Biology Physics, 2022, 112, 262-263.	0.8	0
4	Application of Artificial Intelligence for Nasopharyngeal Carcinoma Management – A Systematic Review. Cancer Management and Research, 2022, Volume 14, 339-366.	1.9	9
5	Management of Nasopharyngeal Carcinoma in Elderly Patients. Frontiers in Oncology, 2022, 12, 810690.	2.8	5
6	A novel nomogram to predict overall survival in head and neck cancer survivors with radiation-induced brain necrosis. Radiotherapy and Oncology, 2022, 168, 121-129.	0.6	4
7	Dose-volume predictors of post-radiation primary hypothyroidism in head and neck cancer: A systematic review. Clinical and Translational Radiation Oncology, 2022, 33, 83-92.	1.7	4
8	Maintenance Capecitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma—Magic Bullet or Pandora's Box?. JAMA Oncology, 2022, , .	7.1	2
9	Exploratory Study of NPC-0501 Trial: Optimal Cisplatin Dose of Concurrent and Induction/Adjuvant Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma. Clinical Cancer Research, 2022, 28, 2679-2689.	7.0	4
10	Identifying Patients With Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma by Plasma Epstein-Barr Virus DNA for Chemotherapy Deintensification: <i>Quo Vadis</i> ?. Journal of Clinical Oncology, 2022, 40, 1135-1138.	1.6	1
11	Disadvantaged Subgroups Within the Global Head and Neck Cancer Population: How Can We Optimize Care?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 501-510.	3.8	1
12	The Janus Face in Defining the Optimal Radiation Dose for Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2022, 113, 114-116.	0.8	2
13	Prognostic Biomarkers for Survival in Nasopharyngeal Carcinoma: A Systematic Review of the Literature. Cancers, 2022, 14, 2122.	3.7	7
14	A Single-Arm Phase 2 Trial on Induction Chemotherapy Followed by Concurrent Chemoradiation in Nasopharyngeal Carcinoma Using a Reduced Cumulative Dose of Cisplatin. Frontiers in Oncology, 2022, 12, 842281.	2.8	1
15	Proton Therapy for Squamous Cell Carcinoma of the Head and Neck: Early Clinical Experience and Current Challenges. Cancers, 2022, 14, 2587.	3.7	9
16	Diagnosis and Staging of Nasopharyngeal Cancer. Practical Guides in Radiation Oncology, 2021, , 1-21.	0.1	0
17	Dietary fiber intake from fresh and preserved food and risk of nasopharyngeal carcinoma: observational evidence from a Chinese population. Nutrition Journal, 2021, 20, 14.	3.4	9
18	Contemporary management of the neck in nasopharyngeal carcinoma. Head and Neck, 2021, 43, 1949-1963.	2.0	4

#	Article	IF	CITATIONS
19	Standardization for oncologic head and neck surgery. European Archives of Oto-Rhino-Laryngology, 2021, 278, 4663-4669.	1.6	2
20	Re-irradiation versus surgery for locally recurrent nasopharyngeal carcinoma. Lancet Oncology, The, 2021, 22, e217.	10.7	0
21	International Recommendations on Reirradiation by Intensity Modulated Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2021, 110, 682-695.	0.8	42
22	Current Trends and Controversies in the Management of Warthin Tumor of the Parotid Gland. Diagnostics, 2021, 11, 1467.	2.6	17
23	External Validation of a Nomogram to Predict Survival and Benefit of Concurrent Chemoradiation for Stage II Nasopharyngeal Carcinoma. Cancers, 2021, 13, 4286.	3.7	4
24	Can Radiation Therapy Quality Assurance Improve Nasopharyngeal Cancer Outcomes in Low- and Middle-Income Countries: Reporting the First Phase of a Prospective International Atomic Energy Agency Study. International Journal of Radiation Oncology Biology Physics, 2021, 111, 1227-1236.	0.8	5
25	A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma. European Journal of Cancer, 2021, 153, 109-122.	2.8	48
26	Low vitamin D exposure and risk of nasopharyngeal carcinoma: Observational and genetic evidence from a multicenter case–control study. Clinical Nutrition, 2021, 40, 5180-5188.	5.0	1
27	Prognostic Factors for Overall Survival in Nasopharyngeal Cancer and Implication for TNM Staging by UICC: A Systematic Review of the Literature. Frontiers in Oncology, 2021, 11, 703995.	2.8	25
28	Dose-Response Reduction in Risk of Nasopharyngeal Carcinoma From Smoking Cessation: A Multicenter Case-Control Study in Hong Kong, China. Frontiers in Oncology, 2021, 11, 699241.	2.8	2
29	Prognostic and therapeutic evaluation of nasopharyngeal carcinoma by dynamic contrast-enhanced (DCE), diffusion-weighted (DW) magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS). Magnetic Resonance Imaging, 2021, 83, 50-56.	1.8	11
30	Treatment of persistent/recurrent nodal disease in nasopharyngeal cancer. Current Opinion in Otolaryngology and Head and Neck Surgery, 2021, 29, 86-92.	1.8	0
31	Automatic segmentation for adaptive planning in nasopharyngeal carcinoma IMRT: Time, geometrical, and dosimetric analysis. Medical Dosimetry, 2020, 45, 60-65.	0.9	26
32	Dose volume effects of reâ€irradiation for locally recurrent nasopharyngeal carcinoma. Head and Neck, 2020, 42, 180-187.	2.0	11
33	Potential pitfalls in incorporating plasma Epsteinâ€Barr virus DNA in the management of nasopharyngeal carcinoma. Head and Neck, 2020, 42, 446-455.	2.0	6
34	Solar Ultraviolet Radiation and Vitamin D Deficiency on Epstein-Barr Virus Reactivation: Observational and Genetic Evidence From a Nasopharyngeal Carcinoma-Endemic Population. Open Forum Infectious Diseases, 2020, 7, ofaa426.	0.9	7
35	Metastatic Squamous Cell Carcinoma to the Cervical Lymph Nodes From an Unknown Primary Cancer: Management in the HPV Era. Frontiers in Oncology, 2020, 10, 593164.	2.8	23
36	Second primary cancer after intensity-modulated radiotherapy for nasopharyngeal carcinoma: A territory-wide study by HKNPCSG. Oral Oncology, 2020, 111, 105012.	1.5	16

#	Article	IF	CITATIONS
37	913MO Second primary cancer after intensity-modulated radiotherapy for nasopharyngeal carcinoma in Hong Kong (2001-2010): A territory-wide study by HKNPCSG. Annals of Oncology, 2020, 31, S659-S660.	1.2	0
38	Proton/heavy ion therapy in salvage of locally recurrent nasopharyngeal carcinoma. Annals of Nasopharynx Cancer, 2020, 4, 4-4.	0.3	2
39	Radiotherapy in the management of glottic squamous cell carcinoma. Head and Neck, 2020, 42, 3558-3567.	2.0	9
40	Nasopharyngeal carcinoma MHC region deep sequencing identifies HLA and novel non-HLA TRIM31 and TRIM39 loci. Communications Biology, 2020, 3, 759.	4.4	17
41	Clinical utility of serial analysis of circulating tumour cells for detection of minimal residual disease of metastatic nasopharyngeal carcinoma. British Journal of Cancer, 2020, 123, 114-125.	6.4	14
42	NPCâ€0501 trial on the value of changing chemoradiotherapy sequence, replacing 5â€fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma. Cancer, 2020, 126, 3674-3688.	4.1	37
43	Current management of stage IV nasopharyngeal carcinoma without distant metastasis. Cancer Treatment Reviews, 2020, 85, 101995.	7.7	28
44	<scp>COVID</scp> â€19 pandemic: Effects and evidenceâ€based recommendations for otolaryngology and head and neck surgery practice. Head and Neck, 2020, 42, 1259-1267.	2.0	218
45	Network-meta-analysis of chemotherapy in nasopharyngeal carcinoma (MAC-NPC): An update on 8,221 patients Journal of Clinical Oncology, 2020, 38, 6523-6523.	1.6	14
46	Induction Chemotherapy Docetaxel, Cisplatin, 5-Fluorouracil Followed by Concurrent Chemoradiotherapy in Stage IVA Nasopharyngeal Carcinoma. Clinical Oncology and Research, 2020, , 1-8.	0.0	0
47	Crucifera sulforaphane (SFN) inhibits the growth of nasopharyngeal carcinoma through DNA methyltransferase 1 (DNMT1)/Wnt inhibitory factor 1 (WIF1) axis. Phytomedicine, 2019, 63, 153058.	5.3	19
48	Patterns of care and treatment outcomes for local recurrence of NPC after definite IMRT—A study by the HKNPCSG. Head and Neck, 2019, 41, 3661-3669.	2.0	28
49	International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2019, 105, 567-580.	0.8	96
50	Management of locally recurrent nasopharyngeal carcinoma. Cancer Treatment Reviews, 2019, 79, 101890.	7.7	186
51	International Consensus on Delineation of Target Volumes and Organs at Risk. , 2019, , 239-261.		2
52	Milk Consumption Across Life Periods in Relation to Lower Risk of Nasopharyngeal Carcinoma: A Multicentre Case-Control Study. Frontiers in Oncology, 2019, 9, 253.	2.8	9
53	Advances in Radiotherapy. , 2019, , 263-288.		2
54	Salvage of Local Recurrence. , 2019, , 289-312.		1

#	Article	IF	CITATIONS
55	Special section on intensity-modulated radiation therapy for head and neck cancer (IMRT). Oral Oncology, 2019, 88, 49-50.	1.5	3
56	A Mixed-Methods Study of Unmet Supportive Care Needs Among Head and Neck Cancer Survivors. Cancer Nursing, 2019, 42, 67-78.	1.5	31
57	Head and neck cancer in Hong Kong. Japanese Journal of Clinical Oncology, 2018, 48, 13-21.	1.3	10
58	Prospective, Multicenter, Phase 2 Trial of Induction Chemotherapy Followed by Bio-Chemoradiotherapy for Locally Advanced Recurrent Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2018, 100, 630-638.	0.8	34
59	Concurrent-Adjuvant Chemoradiation Therapy for Stage III-IVB Nasopharyngeal Carcinoma—Exploration for Achieving Optimal 10-Year Therapeutic Ratio. International Journal of Radiation Oncology Biology Physics, 2018, 101, 1078-1086.	0.8	23
60	Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study). Oral Oncology, 2018, 77, 16-21.	1.5	189
61	International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. Radiotherapy and Oncology, 2018, 126, 25-36.	0.6	214
62	Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial. Journal of Clinical Oncology, 2018, 36, 3091-3100.	1.6	147
63	Test-retest reliability of a computer-assisted self-administered questionnaire on early life exposure in a nasopharyngeal carcinoma case-control study. Scientific Reports, 2018, 8, 7052.	3.3	8
64	Leukocyte telomere length associates with nasopharyngeal carcinoma risk and survival in <scp>H</scp> ong <scp>K</scp> ong <scp>C</scp> hinese. International Journal of Cancer, 2018, 143, 2289-2298.	5.1	9
65	Cost minimization analysis of capecitabine versus 5-fluorouracil-based treatment for gastric cancer patients in Hong Kong. Journal of Medical Economics, 2017, 20, 541-548.	2.1	3
66	Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer. Oral Oncology, 2017, 67, 52-60.	1.5	46
67	Reirradiation with intensityâ€modulated radiotherapy for locally recurrent T3 to T4 nasopharyngeal carcinoma. Head and Neck, 2017, 39, 533-540.	2.0	57
68	Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis. Journal of the National Cancer Institute, 2017, 109, .	6.3	37
69	What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis. Journal of Clinical Oncology, 2017, 35, 498-505.	1.6	263
70	MicroRNA profiling study reveals miR-150 in association with metastasis in nasopharyngeal carcinoma. Scientific Reports, 2017, 7, 12012.	3.3	13
71	A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10â€year outcomes for efficacy and toxicity. Cancer, 2017, 123, 4147-4157.	4.1	70
72	Challenges for Quality Assurance of Target Volume Delineation in Clinical Trials. Frontiers in Oncology, 2017, 7, 221.	2.8	28

#	Article	IF	CITATIONS
73	A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiation (CRT) Journal of Clinical Oncology, 2017, 35, 6002-6002.	1.6	13
74	Adjuvant S-1 chemotherapy after curative resection of gastric cancer in Chinese patients: assessment of treatment tolerability and associated risk factors. Hong Kong Medical Journal, 2017, 23, 54-62.	0.1	5
75	Proposal for the 8th edition of the <scp>AJCC</scp> / <scp>UICC</scp> staging system for nasopharyngeal cancer in the era of intensityâ€modulated radiotherapy. Cancer, 2016, 122, 546-558.	4.1	254
76	Active surveillance of carbapenem-resistant Enterobacteriaceae in intensive care units: ls it cost-effective in a nonendemic region?. American Journal of Infection Control, 2016, 44, 394-399.	2.3	31
77	IKBB tumor suppressive role in nasopharyngeal carcinoma <i>via</i> NF-κB-mediated signalling. International Journal of Cancer, 2016, 138, 160-170.	5.1	12
78	Whole-exome sequencing identifies multiple loss-of-function mutations of NF-κB pathway regulators in nasopharyngeal carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 11283-11288.	7.1	144
79	Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensityâ€modulated radiotherapy. Cancer, 2016, 122, 3307-3315.	4.1	125
80	Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review. Oral Oncology, 2016, 53, 10-16.	1.5	86
81	Whole-exome sequencing identifies <i>MST1R</i> as a genetic susceptibility gene in nasopharyngeal carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 3317-3322.	7.1	71
82	Comparison of Planning Quality and Efficiency Between Conventional and Knowledge-based Algorithms in Nasopharyngeal Cancer Patients Using Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 95, 981-990.	0.8	126
83	Metastasis-suppressing <i>NID2</i> , an epigenetically-silenced gene, in the pathogenesis of nasopharyngeal carcinoma and esophageal squamous cell carcinoma. Oncotarget, 2016, 7, 78859-78871.	1.8	33
84	The International Atomic Energy Agency global initiatives on nasopharyngeal cancer treatment. Chinese Clinical Oncology, 2016, 5, 27-27.	1.2	4
85	Management of Nasopharyngeal Carcinoma. , 2016, , 445-473.		0
86	Comparative methylome analysis in solid tumors reveals aberrant methylation at chromosome 6p in nasopharyngeal carcinoma. Cancer Medicine, 2015, 4, 1079-1090.	2.8	76
87	Clinical utility of plasma Epsteinâ€Barr virus DNA and <i>ERCC1</i> single nucleotide polymorphism in nasopharyngeal carcinoma. Cancer, 2015, 121, 2720-2729.	4.1	43
88	NF-κB p65 Subunit Is Modulated by Latent Transforming Growth Factor-β Binding Protein 2 (LTBP2) in Nasopharyngeal Carcinoma HONE1 and HK1 Cells. PLoS ONE, 2015, 10, e0127239.	2.5	29
89	Chemotherapy for Nasopharyngeal Carcinoma – Current Recommendation and Controversies. Hematology/Oncology Clinics of North America, 2015, 29, 1107-1122.	2.2	39
90	Chemotherapy for Nasopharyngeal Cancer: Neoadjuvant, Concomitant, and/or Adjuvant. Current Treatment Options in Oncology, 2015, 16, 44.	3.0	16

#	Article	IF	CITATIONS
91	Preliminary results of trial NPCâ€0501 evaluating the therapeutic gain by changing from concurrentâ€adjuvant to inductionâ€concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma. Cancer, 2015, 121, 1328-1338.	4.1	152
92	Therapeutic targeting of CBP/β-catenin signaling reduces cancer stem-like population and synergistically suppresses growth of EBV-positive nasopharyngeal carcinoma cells with cisplatin. Scientific Reports, 2015, 5, 9979.	3.3	59
93	Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncology, The, 2015, 16, 645-655.	10.7	593
94	Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective. Journal of Clinical Oncology, 2015, 33, 3356-3364.	1.6	579
95	Epigenetic markers for noninvasive early detection of nasopharyngeal carcinoma by methylationâ€sensitive high resolution melting. International Journal of Cancer, 2015, 136, E127-35.	5.1	72
96	Abstract 4773: Aberrant methylation at chromosome 6p as novel biomarkers for diagnosis and prognosis of nasopharyngeal carcinoma. , 2015, , .		1
97	Abstract 1734: Preclinical study of HSP-90 inhibitor drug, AUY922 showed good efficacy in treatment of nasopharyngeal cancer. , 2015, , .		0
98	Multigene pathwayâ€based analyses identify nasopharyngeal carcinoma risk associations for cumulative adverse effects of <i>TERTâ€CLPTM1L</i> and DNA doubleâ€strand breaks repair. International Journal of Cancer, 2014, 135, 1634-1645.	5.1	26
99	The impact of dosimetric inadequacy on treatment outcome of nasopharyngeal carcinoma with IMRT. Oral Oncology, 2014, 50, 506-512.	1.5	83
100	Evolution of treatment for nasopharyngeal cancer – Success and setback in the intensity-modulated radiotherapy era. Radiotherapy and Oncology, 2014, 110, 377-384.	0.6	300
101	Translational research in nasopharyngeal carcinoma. Oral Oncology, 2014, 50, 345-352.	1.5	9
102	Should all nasopharyngeal carcinoma with masticator space involvement be staged as T4?. Oral Oncology, 2014, 50, 1188-1195.	1.5	30
103	Quality of life in head and neck cancer survivors at 1Âyear after treatment: the mediating role of unmet supportive care needs. Supportive Care in Cancer, 2014, 22, 2917-2926.	2.2	38
104	Staging of nasopharyngeal carcinoma – The past, the present and the future. Oral Oncology, 2014, 50, 549-554.	1.5	47
105	Meta-analysis of chemotherapy in nasopharyngeal carcinoma (MAC-NPC): An update on 4,798 patients Journal of Clinical Oncology, 2014, 32, 6022-6022.	1.6	5
106	Single-nucleotide polymorphism (SNP) of excision repair cross complementation group 1 (ERCC1) in nasopharynx cancer (NPC): A companion biomarker study to Hong Kong NPC Study Group 0502 trial Journal of Clinical Oncology, 2014, 32, 6029-6029.	1.6	1
107	Limitation of radiological T3 subclassification of rectal cancer due to paucity of mesorectal fat in Chinese patients. Hong Kong Medical Journal, 2014, 20, 366-70.	0.1	6
108	Abstract 4148: Adverse effects of TERT-CLPTM1L and double-strand breaks repair contribute to risk for nasopharyngeal carcinoma. , 2014, , .		0

#	Article	IF	CITATIONS
109	Five-year Treatment Outcomes for Stage II to III Rectal Cancer in a Single Cancer Institution. Hong Kong Journal of Radiology, 2014, 17, 255-266.	0.1	0
110	Role of MIF/CXCL8/CXCR2 signaling in the growth of nasopharyngeal carcinoma tumor spheres. Cancer Letters, 2013, 335, 81-92.	7.2	47
111	Is Selective Neck Irradiation Safe for Node-Negative Nasopharyngeal Carcinoma?. International Journal of Radiation Oncology Biology Physics, 2013, 85, 902-903.	0.8	13
112	Predictive factors and radiological features of radiation-induced cranial nerve palsy in patients with nasopharyngeal carcinoma following radical radiotherapy. Oral Oncology, 2013, 49, 49-54.	1.5	34
113	Perceived unmet supportive care needs and determinants of quality of life among head and neck cancer survivors: a research protocol. Journal of Advanced Nursing, 2013, 69, 2750-2758.	3.3	6
114	A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation. Molecular Cancer, 2013, 12, 128.	19.2	54
115	Treatment Outcomes of Primary Pulmonary Lymphoepithelioma-like Carcinoma: a Series of 22 Patients and Treatment Strategy Review. Hong Kong Journal of Radiology, 2013, 16, 270-277.	0.1	3
116	Treatment of primary liver cancer using highly-conformal radiotherapy with kv-image guidance and respiratory control. Radiotherapy and Oncology, 2012, 102, 56-61.	0.6	34
117	The battle against nasopharyngeal cancer. Radiotherapy and Oncology, 2012, 104, 272-278.	0.6	191
118	Nasopharyngeal carcinoma: Salvage of local recurrence. Oral Oncology, 2012, 48, 768-774.	1.5	50
119	The strength/weakness of the AJCC/UICC staging system (7th edition) for nasopharyngeal cancer and suggestions for future improvement. Oral Oncology, 2012, 48, 1007-1013.	1.5	109
120	Phase II trial of capecitabine plus cisplatin as firstâ€line therapy in patients with metastatic nasopharyngeal cancer. Head and Neck, 2012, 34, 1225-1230.	2.0	36
121	If concurrent–adjuvant chemoradiotherapy is beneficial for locoregionally advanced nasopharyngeal carcinoma, would changing the sequence to induction–concurrent achieve better outcome?. Journal of Radiation Oncology, 2012, 1, 107-115.	0.7	18
122	Current Management of Nasopharyngeal Cancer. Seminars in Radiation Oncology, 2012, 22, 233-244.	2.2	274
123	Radical radiotherapy for nasopharyngeal carcinoma in elderly patients: The importance of co-morbidity assessment. Oral Oncology, 2012, 48, 162-167.	1.5	38
124	The prognostic value of histological typing in nasopharyngeal carcinoma. Oral Oncology, 2012, 48, 429-433.	1.5	37
125	A phase II study of pemetrexed combined with cisplatin in patients with recurrent or metastatic nanopharyngeal carcinoma. Oral Oncology, 2012, 48, 441-444.	1.5	21
126	Factors contributing to the efficacy of concurrent–adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: Combined analyses of NPC-9901 and NPC-9902 Trials. European Journal of Cancer, 2011, 47, 656-666.	2.8	196

#	Article	IF	CITATIONS
127	A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. Radiotherapy and Oncology, 2011, 98, 15-22.	0.6	102
128	Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Investigational New Drugs, 2011, 29, 1449-1458.	2.6	179
129	An analysis of the efficacy of serial screening for familial nasopharyngeal carcinoma based on Markov chain models. Familial Cancer, 2011, 10, 133-139.	1.9	12
130	Adjuvant chemoradiation for resected gastric cancer: a 10-year experience. Gastric Cancer, 2011, 14, 63-71.	5.3	18
131	Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement. BMC Cancer, 2011, 11, 288.	2.6	24
132	Clinical Outcomes and Patterns of Failure After Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2011, 79, 420-428.	0.8	236
133	Can the Analysis of ERCC1 Expression Contribute to Individualized Therapy in Nasopharyngeal Carcinoma?. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1414-1420.	0.8	20
134	Outcomes of nasopharyngeal carcinoma screening for high risk family members in Hong Kong. Familial Cancer, 2010, 9, 221-228.	1.9	36
135	Impact of adjuvant chemoradiation for adenocarcinoma of stomach after curative gastrectomy in Chinese: A 7â€year audit. Surgical Practice, 2010, 14, 85-91.	0.2	Ο
136	Randomized Trial of Radiotherapy Plus Concurrent-Adjuvant Chemotherapy vs Radiotherapy Alone for Regionally Advanced Nasopharyngeal Carcinoma. Journal of the National Cancer Institute, 2010, 102, 1188-1198.	6.3	298
137	Familial nasopharyngeal carcinoma in Hong Kong: epidemiology and implication in screening. Familial Cancer, 2009, 8, 103-108.	1.9	34
138	Major Late Toxicities After Conformal Radiotherapy for Nasopharyngeal Carcinoma—Patient- and Treatment-Related Risk Factors. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1121-1128.	0.8	95
139	Sensorineural Hearing Loss After Treatment of Nasopharyngeal Carcinoma: A Longitudinal Analysis. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1335-1342.	0.8	98
140	Trends and Patterns of Breast Conservation Treatment in Hong Kong: 1994–2007. International Journal of Radiation Oncology Biology Physics, 2009, 74, 98-103.	0.8	20
141	Nasopharynx. Medical Radiology, 2009, , 57-73.	0.1	Ο
142	Parapharyngeal Extension of Nasopharyngeal Carcinoma: Still a Significant Factor in Era of Modern Radiotherapy?. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1082-1089.	0.8	34
143	Potential improvement of tumor control probability by induction chemotherapy for advanced nasopharyngeal carcinoma. Radiotherapy and Oncology, 2008, 87, 204-210.	0.6	90
144	N-staging by magnetic resonance imaging for patients with nasopharyngeal carcinoma: Pattern of nodal involvement by radiological levels. Radiotherapy and Oncology, 2007, 82, 70-75.	0.6	84

#	Article	IF	CITATIONS
145	Treatment of Stage IV(A–B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation: Impact of chemotherapy schemes. International Journal of Radiation Oncology Biology Physics, 2006, 66, 1004-1010.	0.8	51
146	Induction chemotherapy with cisplatin and gemcitabine followed by accelerated radiotherapy and concurrent cisplatin in patients with stage IV(A-B) nasopharyngeal carcinoma. Head and Neck, 2006, 28, 880-887.	2.0	45
147	Treatment of stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1331-1338.	0.8	66
148	Screening for family members of patients with nasopharyngeal carcinoma. International Journal of Cancer, 2005, 113, 998-1001.	5.1	67
149	Re-irradiation for recurrent NPC—is the treatment merited at all?. Annals of Nasopharynx Cancer, 0, 1, 1-1.	0.3	0
150	Knowledge-based planning in nasopharyngeal carcinoma. Annals of Nasopharynx Cancer, 0, 4, 6-6.	0.3	1
151	Precision radiotherapy in nasopharyngeal carcinoma. Annals of Nasopharynx Cancer, 0, 5, 1-1.	0.3	0